186020-66-6

Basic information

• Product Name: TERT-BUTYL 12-HYDROXY-4 7 10-TRIOXA-
• Synonyms: TERT-BUTYL 12-HYDROXY-4 7 10-TRIOXA-;HO-PEG3-tBu;HO-PEG3-CH2CH2COOtBu;3-[2-[2-(2-Hydroxyethoxy)ethoxy]ethoxy]propionic acid tert-butyl ester;tert-Butyl 12-hydroxy-4,7,10-trioxadodecanoate >=97.0% (GC);Hydroxy-PEG4-t-butylester;Propanoic acid, 3-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]-, 1,1-dimethylethyl ester;tert-Butyl 3-(2-(2-(2-hydroxyethoxy)
• CAS NO: 186020-66-6
• Molecular Formula: C₁₃H₂₆O₆
• Molecular Weight: 278.342
• Mol File: 186020-66-6.mol

Chemical Properties

• Boiling Point: 365.8°C at 760 mmHg
• Flash Point: 125.2°C
• Appearance: /
• Density: 1.052 g/mL at 20 °C(lit.)
• Vapor Pressure: 7.78E-07mmHg at 25°C
• Refractive Index: n20/D 1.446
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 14.36±0.10(Predicted)
• BRN: 7638988
• CAS DataBase Reference: TERT-BUTYL 12-HYDROXY-4 7 10-TRIOXA-(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 12-HYDROXY-4 7 10-TRIOXA-(186020-66-6)
• EPA Substance Registry System: TERT-BUTYL 12-HYDROXY-4 7 10-TRIOXA-(186020-66-6)

Safety Data

• WGK Germany: 3
• F: 10
• Hazardous Substances Data: 186020-66-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 12-HYDROXY-4 7 10-TRIOXAis used as a solubility enhancer for improving the aqueous solubility of hydrophobic drugs. The hydrophilic PEG spacer increases the drug's interaction with water, facilitating better dissolution and absorption.
Used in Chemical Synthesis:
In the field of chemical synthesis, TERT-BUTYL 12-HYDROXY-4 7 10-TRIOXAserves as a versatile building block for the creation of more complex molecules. The hydroxyl group can be further derivatized or replaced with other reactive functional groups, allowing for the development of new compounds with specific properties and applications.
Used in Drug Delivery Systems:
TERT-BUTYL 12-HYDROXY-4 7 10-TRIOXAis used as a component in the design of drug delivery systems. The t-butyl protected carboxyl group can be deprotected under acidic conditions, allowing for the controlled release of drugs in specific environments, such as the acidic conditions of tumor tissues or the endosome/lysosome compartments in cells.
Used in Bioconjugation:
In the field of bioconjugation, TERT-BUTYL 12-HYDROXY-4 7 10-TRIOXAis used as a linker to attach biologically active molecules, such as peptides, proteins, or nucleic acids, to other molecules or surfaces. The hydroxyl group provides a reactive site for covalent attachment, enabling the creation of conjugates with specific properties and functions.

InChI:InChI=1/C13H26O6/c1-13(2,3)19-12(15)4-6-16-8-10-18-11-9-17-7-5-14/h14H,4-11H2,1-3H3

Upstream product

• 1663-39-4 tert-Butyl acrylate 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 

Downstream Products

• 166668-33-3 (E)-17-bromo-4,7,10,13-tetraoxa-15-heptadecenoic acid tert-butyl ester 
• 1274917-84-8 1,4-diiodo-2,5-bis(11-(tert-butoxycarbonyl)-3,6,9-trioxaundecyloxy)benzene 
• 935272-06-3 1,4-diiodo-2,5-bis(11-carboxy-3,6,9-trioxaundecyloxy)benzene 
• 518044-49-0 3-{2-[2-(2-hydroxyethoxyl)ethoxy]ethoxy}propanoic acid 

Relevant articles and documents

A 18F-labeled dibenzocyclooctyne (DBCO) derivative for copper-free click labeling of biomolecules

The new prosthetic group 18F-TEG-DBCO (dibenzocyclooctyne) can be prepared within a total reaction time of 60 min including purification with an overall yield (n.d.c.) of 34 ± 5%. Copper-free click cycloadditions with an azido-cRGD, a folate-az

CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS

Provided are conjugates of camptothecin analogs with a cell-binding molecule of formula (I), wherein R1, R2, R3, R4, R5, X, L, n, m, T and ----- are defined herein. It also provides methods of making the conjugates of camptothecin analogs to a cell-binding agent, as well as methods of using the conjugates in targeted treatment of cancer, infection, and immunological disorders.

PROTAC small molecular compound and application thereof

The invention discloses a compound with a general formula I, or a pharmaceutically acceptable salt, a stereoisomer, an ester, a prodrug, a solvate and a deuterated compound thereof, a composition containing the compound with the general formula I, and application of the compound with the general formula I or the pharmaceutically acceptable salt, stereoisomer, ester, prodrug, solvate and deuteratedcompound thereof in preparation of medicines for treating diseases related to serine/threonine kinase family (MAP4Ks), preferably medicines for treating diseases related to hematopoietic stem cell kinase 1 (HPK1).

A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS

Provided herein is the conjugation of an amanita toxin compound to a cell-binding molecule with branched linkers for having better targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of an amanita molecule to a cell-binding ligand, as well as methods of using the conjugate in targets treatment of cancer, infection and autoimmune disease.

A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS

Provided is a conjugation of cytotoxic drug to a cell-binding molecule with a side-chain linker. It provides side-chain linkage methods of making a conjugate of a cytotoxic molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and immunological disorders.

A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS

The present invention relates to the conjugation of a tubulysin analog compound to a cell-binding molecule with branched/side-chain linkers for having better delivery of the conjugate compound and targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of a tubulysin analog molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and autoimmune disease.

CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES

A novel cross-linked cytotoxic agents, pyrrolobenzo-diazepine dimer (PBD) derivatives, and their conjugates to a cell-binding molecule, a method for preparation of the conjugates and the therapeutic use of the conjugates.

CONJUGATION LINKERS CONTAINING 2,3-DIAMINOSUCCINYL GROUP

Provided is a conjugate of a cytotoxic drug/molecule to a cell-binding molecule with a bis-linker (adual-linker) containing a 2, 3-diaminosuccinyl group. It also relates to preparation of the conjugate of a cytotoxic drug/molecule to a cell-binding molecule with the bis-linker, particularly when the drug having functional groups of amino, hydroxyl, diamino, amino-hydroxyl, dihydroxyl, carboxyl, hydrazine, aldehyde and thiol for conjugation with the bis-linker in a specific manner, as well as the therapeutic use of the conjugates.

COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS

The present disclosure provides novel polypeptide-therapeutic compound or hormone-therapeutic compound conjugates using cleavable or non-cleavable linkers, whereby the polypeptide or hormone serves to target specific cells using receptor expression on the targeted cell to bind the ligand (polypeptide or hormone) carrying the therapeutic compound unlike antibody drug conjugates. Upon binding, the ligand and the therapeutic compound (multiples of the therapeutic compound in some embodiments) enter the cell by receptor-mediated endocytosis, and release drugs conjugated to the ligand by linkers, to interact with intracellular components to enhance, restore, or block a signal transduction process. The ligands for the polypeptide-therapeutic compound or hormone-therapeutic compound conjugates include, but are not limited to: cytokines, growth factors and hormones among other proteins with corresponding cell surface specific receptors. The disorders targeted by such polypeptide-therapeutic compound or hormone-therapeutic compound conjugates include, but are not limited to: immunological disorders (e.g., allergy and autoimmune disorders) and cancer.

A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS

The present invention relates to the conjugation of a tubulysin analog compound to a cell-binding molecule with branched/side-chain linkers for having better delivery of the conjugate compound and targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of a tubulysin analog molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and autoimmune disease.